NCT01526512Unknown2 期
Low Dose of Metronomic Cyclophosphamide and Capecitabine in Pretreated HER2-negative Metastatic Breast Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 72
- 试验地点
- 1
- 主要终点
- PFS
研究概览
简要总结
The purpose of this study is to evaluate the role of low dose metronomic cyclophosphamide and capecitabine in pretreated metastatic breast cancer.
详细描述
Metronomic chemotherapy has been considered as an effective strategy in metastatic breast cancer. This trial is designed to evaluate the role of low dose metronomic cyclophosphamide and capecitabine in pretreated metastatic breast cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Females with age between 18 and 80 years old
- •ECOG performance between 0-3
- •Life expectancy more than 3 months
- •Histological proven unresectable recurrent or advanced HER2-negative breast cancer
- •At least one previous therapy regimen (including endocrine therapy) for metastatic breast cancer;suitable for monotherapy (Neoadjuvant or adjuvant docetaxel should be completed at least one year).
- •At least one measurable disease according to the response evaluation criteria in solid tumor (RECIST1.1)
- •No anticancer therapy within 4 weeks
- •Adequate hematologic, hepatic, and renal function,No serious medical history of heart, lung, liver and kidney
- •Provision of written informed consent prior to any study specific procedures
- •Previous capecitabine is permitted, however, it should be completed at least 6 months.
排除标准
- •Pregnant or lactating women (female patients of child-bearing potential must have a negative serum pregnancy test within 14 days of first day of drug dosing, or, if positive, a pregnancy ruled out by ultrasound)
- •Women of child-bearing potential, unwilling to use adequate contraceptive protection during the course of the study
- •Treatment with an investigational product within 4 weeks before the first treatment
- •Symptomatic central nervous system metastases
- •Other active malignancies (including other hematologic malignancies) or other malignancies, except for cured nonmelanoma skin cancer or cervical intraepithelial neoplasia.
- •Patient having a history of clinically significant cardiovascular, hepatic, respiratory or renal diseases, clinically significant hematological and endocrinal abnormalities, clinically significant neurological or psychiatric conditions
- •Uncontrolled serious infection
- •Patients with bad compliance
- •Patients lack of Dihydropyrimidine Dehydrogenase(DPD)
研究组 & 干预措施
metroCX
Experimental
metroCX Cyclophosphamide 50mg PO d1-28; Capecitabine 1500mg PO d1-28; every 28days
干预措施: metroCX (Drug)
结局指标
主要结局
PFS
时间窗: 6 weeks
次要结局
- Biomarker(1 time)
- Efficacy(6 weeks)
- Safety(3 weeks)
研究者
yanfei Liu
Principal investigator
Fudan University
研究点 (1)
Loading locations...
相似试验
终止
3 期
Low Dose Continuous Cyclophosphamide vs Standard Doxorubicin in Advanced Sarcoma Elderly PatientsSoft Tissue Sarcoma AdultNCT04656262Istituto Oncologico Veneto IRCCS79
终止
2 期
Cyclophosphamide Therapy for Refractory Antibody-Mediated Rejection (AMR) in Kidney TransplantsAntibody Mediated RejectionNCT01630538University of Manitoba4
已完成
4 期
Comparison of Low Dose Versus High Dose Cyclophosphamide as Induction Therapy in the Treatment of Lupus NephritisLupus NephritisNCT02645565Jawaharlal Institute of Postgraduate Medical Education & Research75
Unknown
2 期
Docetaxel With or Without Metronomic Cyclophosphamide as First Line Chemotherapy in Metastatic Breast CancerBreast CancerNCT01526499Fudan University60
进行中（未招募）
1 期
Study with the aim to compare a chemotherapy based on low doses of oral cyclophosphamide administered daily vs standard doxorubicin in elderly patients with advanced soft tissue sarcomas.soft tissue sarcomasMedDRA version: 20.0Level: PTClassification code 10075333Term: Soft tissue sarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-001075-20-ITISTITUTO ONCOLOGICO VENETO - IRCCS132